Publications by authors named "E Safroneeva"

Background: Since the first description of eosinophilic esophagitis (EoE) as clinicopathologic syndrome three decades ago, considerable progress has been made to standardize and validate instruments to assess symptom severity, quality of life, endoscopic, and histologic activity for the purpose of randomized controlled trials (RCTs) and observational studies. Standardized assessment of EoE activity is crucial to be able to compare the results of therapeutic interventions and bring much needed therapies to patients. This review focuses on outcome assessment of disease activity in adults with EoE.

View Article and Find Full Text PDF

Background: In patients with eosinophilic esophagitis (EoE), the correlation between symptoms of esophageal dysfunction and endoscopic and histologic disease activity is generally poor and probably related to multiple causes such as esophageal remodeling processes that might go undetected using endoscopy and histology as well as esophageal hypervigilance and symptom-specific anxiety. Hence, there is a need for a holistic management of patients that goes beyond the control of eosinophilia and symptoms.

Summary And Key Messages: Physiological esophageal testing using high-resolution manometry, functional lumen imaging probe, pH-impedance, wireless pH monitoring, and mucosal impedance may unveil the effects of chronic transmural fibro-inflammatory changes of the esophageal wall as well as esophageal hypervigilance, thereby assisting to phenotype patients, predict therapeutic response to therapy, and identify motility disorders that may need a specific targeted therapy to ameliorate patients' outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Eosinophilic esophagitis (EoE) is a chronic condition driven by food allergies that causes changes in the esophagus, necessitating treatment options like medications, dietary changes, and dilation.
  • Recently approved treatments include oral budesonide tablets (Jorveza) in Europe, Canada, and Australia, and an orodispersible budesonide suspension (Eohilia) in the USA, both shown to effectively induce and maintain remission in EoE patients.
  • Other treatment considerations include off-label proton-pump inhibitors, which have inconsistent results, and Dupilumab, a monoclonal antibody approved for EoE treatment in multiple regions, available for older adolescents and adults who don't respond to
View Article and Find Full Text PDF

Introduction: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS) is a national cohort that was established in 2015 with the aim of improving quality of care of affected adults with eosinophilic esophagitis (EoE). Between 2020 and 2022, paper questionnaires were gradually replaced by fully electronic data capture using Research Electronic Data Capture (REDCap) software. We aim to provide an update of the SEECS 8 years after its launch.

View Article and Find Full Text PDF

Background And Aims: Dysphagia is the hallmark symptom in eosinophilic esophagitis (EoE). However, data are limited regarding the overall prevalence and potential implications of atypical symptoms like odynophagia and retrosternal pain.

Methods: Patients enrolled into the Swiss EoE cohort study (SEECS) were analyzed regarding the presence of odynophagia and retrosternal pain.

View Article and Find Full Text PDF